Senores Pharmaceuticals · tone and specificity signals across the available quarters.
Language signals
Our focus on operational discipline and consistent execution along with sustained momentum in key growth areas and our diversified business verticles enabled us to maintain healthy business performance despite an uncertain operating environment.
For FI27, our initial outlook indicates our revenue growth of approximate 30 to 40%. And our P growth of about 50 to 60%. This confidence is supported by robust order pipeline and a clear visibility on upcoming product launches over the coming quarters.
Let us wait for one or two quarters. Let us see how things settle in the world in today's scenario to talk of a 35% group itself is a very courageous thing I would say.